Jennifer S. Smith, PhD, at the UNC Gillings School of Global Public Health, UNC School of Medicine, and UNC Lineberger Comprehensive Cancer Center, led the phase 3 controlled trial, which showed that self-collection kits and scheduling assistance are key for reaching these populations and preventing cervical cancer.

The study, called EPITOPE, led by senior author A. Wesley Burks, MD, CEO of UNC Health and dean of the UNC School of Medicine, and contributing author Edwin Kim, MD, MS, associate professor of pediatrics in the Division of Pediatric Allergy and Immunology at the UNC School of Medicine, shows superior results in desensitizing children to peanuts. Results were recently published in the New England Journal of Medicine.

Dominique Higgins, MD, PhD, led research into how a specialized diet can induce a new type of programmed cell death to help kill brain tumor cells.

Michael Kappelman, MD, MPH, was the lead PI on the clinical trial, which followed nearly 300 children with Crohn’s to evaluate how their conditions changed in response to anti-TNF biologic treatments alone or in combination with a second immune suppressive medication.

A four-year clinical trial led by Edwin Kim, MD, at the UNC School of Medicine, has found that an increased dosage of a unique type of peanut allergy immunotherapy continues to show promise for children.

A new glioblastoma treatment from Northwest Biotherapeutics improved outcomes for many patients in a phase 3 clinical study, according to a study published in JAMA Oncology. Matt Ewend, MD, in the UNC Department of Neurosurgery and at UNC Lineberger, led the trial site at the N.C. Basnight Cancer Hospital.

This study, called IMPACT, was co-led by A. Wesley Burks, MD, CEO of UNC Health and dean of the UNC School of Medicine. Edwin Kim, MD, is co-author on the paper and leads peanut allergy research at the UNC School of Medicine.

James F. Howard Jr., MD, professor in the UNC Department of Neurology, was principal investigator of the phase 3 trial for the experimental drug efgartigimod, developed by Belgian pharmaceutical company Argenx.

As part of the NIH-sponsored ACTIV-2 clinical trial for COVID-19 outpatients, preliminary data revealed that a new combination monoclonal antibody treatment reduced hospitalizations and death by 78 percent in high-risk patients. ACTIV-2 vice chair David Wohl, MD, leads monoclonal treatment for UNC Health.

Project Alive, a non-profit organization dedicated to finding a cure for Hunter syndrome, has surpassed its goal of raising $2.5 million dollars for a gene therapy clinical trial to be led by UNC School of Medicine researcher Joseph Muenzer, MD, PhD.

The first investigational agent to be evaluated by ACTIV-2 is LY3819253, an experimental monoclonal antibody treatment made by Lilly Research Laboratories in partnership with AbCellera Biologics.

UNC School of Medicine researchers led by Edwin Kim, MD, show that tiny under-the-tongue doses of peanut protein can offer safe and substantial protection against peanut allergy.

Tag: Clinical Trials

HPV Self-Collection Kits Increase Screening Among Under-screened, Under-served Women in North Carolina

12 Months of Treatment with EPIT Superior to Placebo in Desensitizing Children to Peanuts

Researchers Leverage Cell Self-Destruction to Treat Brain Tumors

Researchers Announce Findings from Landmark Clinical Trial for Pediatric Crohn’s Disease

Novel Peanut Allergy Treatment Shown to be Safe, Effective, and Lasting

Ewend Leads UNC Hospitals Site for Successful National Glioblastoma Clinical Trial

Oral Immunotherapy Alleviates Peanut Allergy in Some Young Children

FDA Approves New Drug to Treat Generalized Myasthenia Gravis

Experimental Monoclonal Antibody Combo Shows Significant Efficacy against COVID-19

Community Rallies to Raise $2.5 Million for Gene Therapy Trial at UNC

Wohl launches clinical trial, one of 25 sites nationally testing COVID-19 treatments

New Peanut Allergy Treatment Passes Phase 2 Trial, Shows Effectiveness and Safety